How expensive is inflammatory bowel disease? A critical analysis
about
Indirect costs of inflammatory bowel diseases: Crohn's disease and ulcerative colitis. A systematic reviewManagement of active Crohn disease.A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases.New strategies for treatment of inflammatory bowel diseaseRacial disparities in utilization of specialist care and medications in inflammatory bowel diseaseEffectiveness of anti-TNFα for Crohn disease: research in a pediatric learning health system.Coping strategies, satisfaction with life, and quality of life in Crohn's disease: A gender perspective using structural equation modeling analysis.Serologic markers: impact on early diagnosis and disease stratification in inflammatory bowel disease.MMX® Mesalazine: a review of its use in the management of mild to moderate ulcerative colitis.Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease.Immunosuppressive and biologic therapy for ulcerative colitis.Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis.New therapeutic avenues in ulcerative colitis: thinking out of the box.Indirect health costs in ulcerative colitis and Crohn's disease: a systematic review and meta-analysis.Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.Comparison of the Multiattribute Utility Instruments EQ-5D and SF-6D in a Europe-Wide Population-Based Cohort of Patients with Inflammatory Bowel Disease 10 Years after Diagnosis.Monitoring-Based Model for Personalizing the Clinical Process of Crohn's Disease.Biological and Immunomodulator Use in Crohn's Disease in a Medicaid Population.Surgical treatment of ulcerative colitis in the biologic therapy era.Estimating benefits of therapy in Crohn's disease in terms of indirect costs.The economic burden of inflammatory bowel disease: clear problem, unclear solution.Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom Study.The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn's disease.Health care costs and their predictors of inflammatory bowel diseases in Germany.Durability of infliximab dose intensification in Crohn's disease.Trends in prevalence, mortality, health care utilization and health care costs of Swiss IBD patients: a claims data based study of the years 2010, 2012 and 2014.Daily hassles score associates with the somatic and psychological health of patients with Crohn's disease.Factors Associated With Length of Stay in Veterans With Inflammatory Bowel Disease Hospitalized for an Acute Flare.Thrombin mediates vagal apoptosis and dysfunction in inflammatory bowel disease.Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers.Nutritional intake according to injury extent in ulcerative colitis patients.
P2860
Q26749259-BC0E62C0-C00D-4BB4-976A-45BDD85F621BQ34345967-9FBE3772-37A9-4831-AFA2-83504B704034Q34353032-779A71EA-3E1B-44CD-B049-9585281B3552Q35069777-D8018C2E-8CDB-42C9-B48F-10C2BA4A0CC7Q35205595-D628AAE1-20B0-448F-BAE1-344B165F2815Q35935859-3500C859-68D8-4568-9A27-BE4734606D1AQ36292871-06935642-2BF3-4896-93F6-0278A85A87EBQ37777013-937F5762-61B9-4D9D-9DA2-E596C8A9BC8EQ37833064-3A91453C-81C9-494D-873A-A3BC8FFF2FDFQ37947158-6E8E2B11-A3A5-4840-8A6C-23B3875AAEB6Q38060831-522671A8-4CBD-48A5-A45F-5EFDA7F07FBCQ38122070-D67DB6DD-FB39-4A00-80AB-06B61517CA9BQ38150670-B415241E-F7F4-458F-B937-128CFED9AD0CQ38345847-132BC14F-9ABC-4B4B-BA00-1DA027C2A603Q39012932-1DFCA8FA-22E9-46F5-86D2-6F880BEF15A3Q39388069-BFF82E26-9268-45E8-88E3-2C032533745AQ39415211-D56EDBC3-8B6D-4BC8-B914-02C1B9CBA163Q39969268-075753E5-02E5-4B67-AD1D-EB6599373DBEQ42728456-6FF59311-68A7-406F-8CFF-FA0865555680Q42930990-D763802F-FE78-49BA-91B0-B240DDFFA173Q43422595-8E85CE32-F4FD-45FB-9C19-5127366B4B8CQ44332424-F682F626-9766-4C9C-831C-C69AD97C40D4Q44363349-BB0E3E14-946B-432C-92B7-213B0A22AF41Q45961306-B8DED3F3-2412-445F-AE86-F70FCFC8FF9AQ46354771-22702CC8-D7E5-4DFA-A7DB-BCA2554AE79FQ47138456-0F1C0C2F-2324-4877-8DBE-D3424A8E9A10Q47246751-D8C5CA2B-E642-4EA9-A3E4-19FD9C84B5A6Q47670155-79986255-FE64-4E18-877C-3632754EBBA7Q48721933-36A5D02D-AFBD-4695-9016-0CFB11563E6AQ51165811-83BEE33F-AEFF-4A50-81A0-C8F2A6D2FBE2Q51252824-B3D37D96-2D86-40F7-B203-29DB418C7E06
P2860
How expensive is inflammatory bowel disease? A critical analysis
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
How expensive is inflammatory bowel disease? A critical analysis
@en
How expensive is inflammatory bowel disease? A critical analysis.
@nl
type
label
How expensive is inflammatory bowel disease? A critical analysis
@en
How expensive is inflammatory bowel disease? A critical analysis.
@nl
prefLabel
How expensive is inflammatory bowel disease? A critical analysis
@en
How expensive is inflammatory bowel disease? A critical analysis.
@nl
P2860
P356
P1476
How expensive is inflammatory bowel disease? A critical analysis
@en
P2093
Selwyn Odes
P2860
P304
P356
10.3748/WJG.14.6641
P407
P577
2008-11-01T00:00:00Z